Rapt Therapeutics $RAPT Shares Sold by Column Group LLC

Column Group LLC lowered its stake in Rapt Therapeutics (NASDAQ:RAPT) by 87.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 166,075 shares of the company’s stock after selling 1,162,538 shares during the quarter. Rapt Therapeutics makes up approximately 5.3% of Column Group LLC’s investment portfolio, making the stock its 4th largest position. Column Group LLC’s holdings in Rapt Therapeutics were worth $4,283,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Boone Capital Management LLC acquired a new position in Rapt Therapeutics during the 3rd quarter worth approximately $20,180,000. Invesco Ltd. bought a new position in Rapt Therapeutics in the 3rd quarter valued at approximately $3,625,000. SummitTX Capital L.P. acquired a new stake in Rapt Therapeutics in the third quarter valued at approximately $2,370,000. Ameriprise Financial Inc. acquired a new stake in Rapt Therapeutics in the third quarter valued at approximately $1,326,000. Finally, UBS Group AG grew its stake in shares of Rapt Therapeutics by 680.3% during the third quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after buying an additional 25,116 shares during the last quarter. 99.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. HC Wainwright cut Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price target for the company. in a research note on Tuesday, January 20th. Guggenheim lowered Rapt Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Piper Sandler downgraded Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 target price for the company. in a research report on Tuesday, January 20th. Clear Str lowered Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Wells Fargo & Company cut Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price target on the stock. in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $48.44.

Rapt Therapeutics Price Performance

Shares of Rapt Therapeutics stock opened at $58.02 on Friday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $58.02. The company’s fifty day moving average is $52.37 and its 200 day moving average is $36.15.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.